Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Pravafenix
Pravafenix 40 mg/160 mg hard capsules · Abschnitt 4.3 · PDF-Seite 3
HOS-123817 · Präparat HOS-095735
- Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
- Severe hepatic impairment including biliary cirrhosis or active liver disease including unexplained
persistent elevations in liver function tests (including serum transaminase elevation) exceeding 3
fold the upper limit of normal (ULN) (see section 4.4).
- Children and adolescents (age below 18 years).
- Moderate to severe renal impairment (defined as an estimated creatinine clearance < 60 ml/min).
- Known photo allergy or photo toxic reaction during treatment with fibrates or ketoprofen.
- Gallbladder disease (see section 4.4).
- Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe
hypertriglyceridaemia (see section 4.4).
- Pregnancy and breast-feeding (see section 4.6).
- Personal history of myopathy and/or rhabdomyolysis with statins and/or fibrates or confirmed
creatine phosphokinase (CK) elevation above 5 times the ULN under previous statin treatment
(see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoprofen (HOS-089671) creatine (HOS-123819) creatinine (HOS-086273)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-17T01:00:00Z · SHA-256 555d912c3c1635440482163c25a3d73a1dd04513baaad39957f8d1035f451ae2 · Passage c8b991b259d6c53ee7cc14bdec49009ce3c9b36ba7284918a188bd2dc0fb14fe · Zeichen 0–1081 im Abschnitt
Gegenanzeigen · Cholib
Cholib 145 mg/20 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-126950 · Präparat HOS-096355
• Hypersensitivity to the active substances, peanut, soya or to any of the excipients listed in
section 6.1 (see also section 4.4)
• Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen
• Active liver disease or unexplained persistent elevations of serum transaminases
• Known gallbladder disease
• Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe
hypertriglyceridaemia
• Moderate to severe renal insufficiency (estimated glomerular filtration rate
< 60 mL/min/1.73 m2)
• Concomitant administration of potent CYP3A4 inhibitors (agents that increase AUC
approximately 5 fold or greater) (e.g. itraconazole, ketoconazole, posaconazole, voriconazole,
HIV protease inhibitors (e.g. nelfinavir), boceprevir, telaprevir, erythromycin, clarithromycin,
telithromycin, nefazodone, and medicinal products containing cobicistat) (see sections 4.4 and
4.5)
• Concomitant administration of gemfibrozil, ciclosporin, or danazol (see sections 4.4 and 4.5)
• Concomitant administration of glecaprevir/ pibrentasvir (see section 4.5)
• Paediatric population (age below 18 years)
• Pregnancy and breast-feeding (see section 4.6)
• Personal history of myopathy and/or rhabdomyolysis with statins and/or fibrates or confirmed
creatine phosphokinase elevation above 5 times the upper limit of normal (ULN) under previous
statin treatment (see section 4.4)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoprofen (HOS-089671) nefazodone (HOS-084519) nelfinavir (HOS-084520) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) cobicistat (HOS-088111) creatine (HOS-123819) gemfibrozil (HOS-088403) glecaprevir (HOS-086297) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T10:28:00Z · SHA-256 348750d8a2030faed77c9c061fe6342a446d1448175630ef5f5390d9ff5afaad · Passage 01cd865d152730ea7f87e81073b6bc3ccb3f2ff3a9e8e7ee83649a48ba092bdb · Zeichen 0–1506 im Abschnitt
Gegenanzeigen · Cholib
Cholib 145 mg/40 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 25
HOS-127022 · Präparat HOS-096355
• Hypersensitivity to the active substances, peanut, soya or to any of the excipients listed in
section 6.1 (see also section 4.4)
• Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen
• Active liver disease or unexplained persistent elevations of serum transaminases
• Known gallbladder disease
• Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe
hypertriglyceridaemia
• Moderate to severe renal insufficiency (estimated glomerular filtration rate
< 60 mL/min/1.73 m2)
• Concomitant administration of potent CYP3A4 inhibitors (agents that increase AUC
approximately 5 fold or greater) (e.g. itraconazole, ketoconazole, posaconazole, voriconazole,
HIV protease inhibitors (e.g. nelfinavir), boceprevir, telaprevir, erythromycin, clarithromycin,
telithromycin, nefazodone, and medicinal products containing cobicistat) (see sections 4.4 and
4.5)
• Concomitant administration of gemfibrozil, ciclosporin, or danazol (see sections 4.4 and 4.5)
• Concomitant administration of glecaprevir, pibrentasvir, elbasvir or grazoprevir (see section
4.5)
• Paediatric population (age below 18 years)
• Pregnancy and breast-feeding (see section 4.6)
• Personal history of myopathy and/or rhabdomyolysis with statins and/or fibrates or confirmed
creatine phosphokinase elevation above 5 times the upper limit of normal (ULN) under previous
statin treatment (see section 4.4)
Concomitant administration of amiodarone, verapamil, amlodipine or diltiazem (see section 4.5)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) ketoprofen (HOS-089671) nefazodone (HOS-084519) elbasvir (HOS-108814) nelfinavir (HOS-084520) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) cobicistat (HOS-088111) amlodipine (HOS-086287) creatine (HOS-123819) gemfibrozil (HOS-088403) glecaprevir (HOS-086297) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) danazol (HOS-085473) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) amiodarone (HOS-085596) posaconazole (HOS-085622) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T10:28:00Z · SHA-256 348750d8a2030faed77c9c061fe6342a446d1448175630ef5f5390d9ff5afaad · Passage b3e383eea6addd5e17e74e7e066bd16291ed5af47e0e656fd20c321af353dadc · Zeichen 0–1610 im Abschnitt
Wechselwirkungen · Rxulti
RXULTI 0.25 mg film-coated tablets RXULTI 0.5 mg film-coated tablets RXULTI 1 mg film-coated tablets RXULTI 2 mg film-coated tablets RXULTI 3 mg film-coated tablets RXULTI 4 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-132042 · Präparat HOS-097184
If brexpiprazole is administered concomitantly with medicinal products known to increase creatine
phosphokinase (CPK), e.g. statins like simvastatin, the possible additive effect with CPK increase
induced by brexpiprazole should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): simvastatin (HOS-086158) creatine (HOS-123819)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-12T14:38:00Z · SHA-256 d060cc667cc18af4e73efacd249c6f69ccb808c8be005b26cc608ba465837472 · Passage f5acc5797192675c9dbb760fb0444369feda8a75433080f45f4d1d393be22432 · Zeichen 2742–2985 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.